Predictions
BioNTech SE ADR
Start price
Target price
Perf. (%)
€92.40
26.02.21
26.02.21
€150.00
26.02.22
26.02.22
40.64%
27.02.22
27.02.22
Market Leader or Top 3
Very small cyclical dependencies
Very Future proof/growth oriented business model
High risks for its business
BioNTech SE ADR
Start price
Target price
Perf. (%)
€97.25
15.02.21
15.02.21
€208.00
30.04.22
30.04.22
103.14%
07.06.21
07.06.21
BioNTech SE ADR
Start price
Target price
Perf. (%)
€99.38
08.02.21
08.02.21
-
08.02.22
08.02.22
26.58%
16.04.21
16.04.21
Innovative
Market Leader or Top 3
Revenue growth > 30% per year expected
High risks in the balance sheet
BioNTech SE ADR
Start price
Target price
Perf. (%)
€96.99
08.02.21
08.02.21
-
08.02.22
08.02.22
2.46%
08.02.21
08.02.21
Innovative
Market Leader or Top 3
Revenue growth > 30% per year expected
High risks in the balance sheet
BioNTech SE ADR
Start price
Target price
Perf. (%)
€87.60
27.01.21
27.01.21
€105.00
27.01.22
27.01.22
201.71%
28.09.21
28.09.21
BioNTech SE ADR
Start price
Target price
Perf. (%)
€87.99
23.01.21
23.01.21
-
23.01.22
23.01.22
108.04%
12.07.21
12.07.21
Top 10 in its market
Known brand
Future proof or reliable business model
EBIT decline > 20% expected
BioNTech SE ADR
Start price
Target price
Perf. (%)
€84.76
13.01.21
13.01.21
€103.00
14.43%
08.02.21
08.02.21
Innovative
Market Leader or Top 3
Revenue growth > 30% per year expected
High risks in the balance sheet
BioNTech SE ADR
Start price
Target price
Perf. (%)
€83.96
09.01.21
09.01.21
€300.00
09.01.22
09.01.22
124.99%
10.01.22
10.01.22
Rising EBIT margin expected
Good rating
High Investments for future growth
Valuable balance sheet
BioNTech SE ADR
Start price
Target price
Perf. (%)
€70.99
31.12.20
31.12.20
€50.00
31.12.21
31.12.21
216.81%
01.01.22
01.01.22
Risky Investment
Below average Marketposition
Little known brand
Outdated or very high risk business model
BioNTech SE ADR
Start price
Target price
Perf. (%)
€70.99
31.12.20
31.12.20
€170.00
31.12.21
31.12.21
216.81%
01.01.22
01.01.22
EBIT growth > 30% per year expected
Rising EBIT margin expected
Very positive Cash Flow expected
Very valuable balance sheet







